GSK (LON:GSK) Earns “Underweight” Rating from JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating restated by JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat Ratings reports.

Separately, Berenberg Bank reduced their price target on GSK from GBX 1,820 ($22.50) to GBX 1,600 ($19.78) and set a “buy” rating for the company in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of GBX 1,805.83 ($22.32).

GSK Trading Up 0.2 %

LON GSK opened at GBX 1,360 ($16.81) on Tuesday. The company has a fifty day moving average of GBX 1,354.65 and a 200 day moving average of GBX 1,482.18. The company has a market capitalization of £55.49 billion, a PE ratio of 1,203.54, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a 1 year low of GBX 1,282.50 ($15.85) and a 1 year high of GBX 1,823.50 ($22.54).

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds bought 7,150 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of GBX 1,394 ($17.23) per share, with a total value of £99,671 ($123,202.72). Insiders purchased 8,658 shares of company stock valued at $11,950,792 in the last three months. 1.61% of the stock is owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.